重症筋無力症治療薬の世界市場2017-2021:抗コリンエステラーゼ薬、免疫抑制剤、免疫グロブリン静注療法(IVIg)...市場調査レポートについてご紹介

【英文タイトル】Global Myasthenia Gravis Drugs Market 2017-2021

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Highlights

PART 05: Pipeline analysis

PART 06: Market landscape
• Global myasthenia gravis drugs market
• Five forces analysis

PART 07: Market segmentation by therapy area
• Anticholinesterases
• Immunosuppressants
• IVIg

PART 08: Geographical segmentation
• Myasthenia gravis drugs market in Americas
• Myasthenia gravis drugs market in EMEA
• Myasthenia gravis drugs market in APAC

PART 09: Market drivers
• Approval of novel monoclonal antibodies
• High unmet medical need
• Growing research activities for the better understanding and diagnosis of myasthenia gravis

PART 10: Impact of drivers

PART 11: Market challenges
• Presence of substitutes
• Limited availability of approved drugs
• Lack of long-term commitment

PART 12: Impact of drivers and challenges

PART 13: Market trends
• Emergence of new entrants
• Growing strategic acquisitions
• Potential treatment options

PART 14: Vendor landscape
• Competitive scenario

PART 15: Key vendor analysis
• Flamel Technologies
• F. Hoffmann-La Roche
• Grifols
• Pfizer
• Shire
• Valeant Pharmaceuticals
• Other prominent vendors

PART 16: Appendix
• List of abbreviations

PART 17: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key customer segments of global myasthenia gravis drugs market
Exhibit 03: Factors affecting the adoption rates of myasthenia gravis drugs market
Exhibit 04: Key pipeline candidates
Exhibit 05: Global myasthenia gravis drugs market snapshot
Exhibit 06: Analysis of global myasthenia gravis drugs market
Exhibit 07: Global myasthenia gravis drugs market 2016-2021 ($ millions)
Exhibit 08: Opportunity analysis of global myasthenia gravis drugs market
Exhibit 09: Opportunity analysis in developed and emerging markets
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global myasthenia gravis drugs market by therapy
Exhibit 12: Segmentation of global myasthenia gravis drugs market based on geography 2016 and 2021
Exhibit 13: Global myasthenia gravis drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: Myasthenia gravis drugs market in Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: Myasthenia gravis drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: Myasthenia gravis drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Key drivers and challenges in APAC
Exhibit 21: Key pipeline monoclonal antibodies
Exhibit 22: Incidence data for myasthenia gravis (annually)
Exhibit 23: Impact of drivers
Exhibit 24: Forcefield analysis of drivers and challenges
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Key entrants in myasthenia gravis drugs market
Exhibit 27: Key acquisitions and their impact
Exhibit 28: Competitive structure analysis of global myasthenia gravis drugs market 2015
Exhibit 29: Competitive analysis of global myasthenia gravis drugs market
Exhibit 30: Market penetration of various myasthenia gravis manufacturers 2015
Exhibit 31: Flamel Technologies: Key highlights
Exhibit 32: Flamel Technologies: Strength assessment
Exhibit 33: Flamel Technologies: Strategy assessment
Exhibit 34: Flamel Technologies: Opportunity assessment
Exhibit 35: F. Hoffmann-La Roche: Strength assessment
Exhibit 36: F. Hoffmann-La Roche: Strategy assessment
Exhibit 37: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 38: F. Hoffmann-La Roche: Year-over-year (YoY) growth and revenue of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 39: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 40: F. Hoffmann-La Roche: YoY growth and revenue of CellCept 2013-2015 ($ millions)
Exhibit 41: Grifols: Key highlights
Exhibit 42: Grifols: Strength assessment
Exhibit 43: Grifols: Strategy assessment
Exhibit 44: Grifols: Opportunity assessment
Exhibit 45: Pfizer: Strength assessment
Exhibit 46: Pfizer: Strategy assessment
Exhibit 47: Pfizer: Opportunity assessment
Exhibit 48: Pfizer: YoY and growth rate of Medrol 2013-2015 ($ millions)
Exhibit 49: Shire: Key highlights
Exhibit 50: Shire: Strength assessment
Exhibit 51: Shire: Strategy assessment
Exhibit 52: Shire: Opportunity assessment
Exhibit 53: Valeant Pharmaceuticals: Strength assessment
Exhibit 54: Valeant Pharmaceuticals: Strategy assessment
Exhibit 55: Valeant Pharmaceuticals: Opportunity assessment


【レポート販売概要】

■ タイトル:重症筋無力症治療薬の世界市場2017-2021:抗コリンエステラーゼ薬、免疫抑制剤、免疫グロブリン静注療法(IVIg)
■ 英文:Global Myasthenia Gravis Drugs Market 2017-2021
■ 発行日:2017年1月12日
■ 調査会社:Technavio
■ 商品コード:IRTNTR11520
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。